Micreos is a biotechnology company that engineers endolysins for targeted treatments against harmful bacteria, including antibiotic-resistant strains. Their innovative approach focuses on two therapeutic areas: Atopic Dermatitis (AD) and Cutaneous T-cell Lymphoma (CTCL). Micreos' endolysin technology selectively targets and kills pathogenic bacteria while preserving beneficial microbiota, offering a new mode of action compared to existing therapies. Their lead product, Staphefekt SA.100, is the first endolysin registered for human use, significantly impacting patients with inflammatory skin conditions. The company is positioned to address the growing concern of antibiotic resistance and improve patient outcomes in chronic bacterial infections.
Something looks off?